Latest Pharma Insights
EU PPWR: Minimizing Medtech Packaging Without Losing Protection
Starting in 2030, the PPWR prohibits unnecessary empty spaces and decorative fillers. In medtech, where size affects sterility, stability, and handling, every void must have a purpose, not just aim for zero empty space. Experts advise that proper documentation is key, and the time to begin is now.
Medtech Insight - August 21, 2026
Starting in 2030, the PPWR prohibits unnecessary empty spaces and decorative fillers. In medtech, where size affects sterility, stability, and handling, every void must have a purpose, not just aim for zero empty space. Experts advise that proper documentation is key, and the time to begin is now.
Medtech Insight - August 21, 2026
US Consumer Health People Moves: Kimberly-Clark, Dude Wipes, InstaMed, Coffee+, Juice Plus+
Kimberly-Clark promotes Suzana Blades to general counsel; Dude Wipes brand expands executive suite for first time since its founding with a chief product officer; and CEO changes at Juice Plus+, InstaMed and Everyday Dose.
HBW Insight - August 21, 2026
Kimberly-Clark promotes Suzana Blades to general counsel; Dude Wipes brand expands executive suite for first time since its founding with a chief product officer; and CEO changes at Juice Plus+, InstaMed and Everyday Dose.
HBW Insight - August 21, 2026
Lilly Goes Deeper Into Infectious Disease With Amplitude
Deal Snapshot: The big pharma continues its investment in infectious disease through a collaboration with Lilly Gateway Labs participant Amplitude, which is working on trans-amplifying RNA vaccines.
Scrip - August 20, 2026
Deal Snapshot: The big pharma continues its investment in infectious disease through a collaboration with Lilly Gateway Labs participant Amplitude, which is working on trans-amplifying RNA vaccines.
Scrip - August 20, 2026
Finance Watch: Venture Capital Investors Meet Biotechs In The Middle
Private Company Edition: Kynexis raised a €40m ($46.7m) series A extension, bringing the round’s total to €97m ($110m), an example of venture capital investors participating in mid-sized rounds, a segment of the capital markets that has been especially difficult.
Scrip - August 20, 2026
Private Company Edition: Kynexis raised a €40m ($46.7m) series A extension, bringing the round’s total to €97m ($110m), an example of venture capital investors participating in mid-sized rounds, a segment of the capital markets that has been especially difficult.
Scrip - August 20, 2026
Agentic AI Lowers Trial Costs By Automating Clinical Research Tasks
A study by Tufts CSDD of Medable’s AI clinical monitoring agents quantifies how much drugmakers can save on clinical trial costs when they adopt agentic artificial intelligence to augment the activities of clinical research associate (CRA) staff.
Scrip - August 20, 2026
A study by Tufts CSDD of Medable’s AI clinical monitoring agents quantifies how much drugmakers can save on clinical trial costs when they adopt agentic artificial intelligence to augment the activities of clinical research associate (CRA) staff.
Scrip - August 20, 2026
Gubra AI Discovery Engine Uncovers Another Promising Obesity Therapy
The Danish firm has initiated a Phase I/IIa trial on a long-acting corticotropin-releasing hormone receptor 2 agonist which shows pipeline-in-a-product potential.
Scrip - August 20, 2026
The Danish firm has initiated a Phase I/IIa trial on a long-acting corticotropin-releasing hormone receptor 2 agonist which shows pipeline-in-a-product potential.
Scrip - August 20, 2026
Ultragenyx Lands Genglycos Approval And Sets Its Sights On A PRV Double
Ultragenyx has gained US FDA approval for its first gene therapy, Genglycos, and the regulator is set to decide on another therapy from the firm by mid-September.
Scrip - August 20, 2026
Ultragenyx has gained US FDA approval for its first gene therapy, Genglycos, and the regulator is set to decide on another therapy from the firm by mid-September.
Scrip - August 20, 2026
EU PPWR: Minimizing Medtech Packaging Without Losing Protection
Starting in 2030, the PPWR prohibits unnecessary empty spaces and decorative fillers. In medtech, where size affects sterility, stability, and handling, every void must have a purpose, not just aim for zero empty space. Experts advise that proper documentation is key, and the time to begin is now.
Medtech Insight - August 21, 2026
Starting in 2030, the PPWR prohibits unnecessary empty spaces and decorative fillers. In medtech, where size affects sterility, stability, and handling, every void must have a purpose, not just aim for zero empty space. Experts advise that proper documentation is key, and the time to begin is now.
Medtech Insight - August 21, 2026
US Consumer Health People Moves: Kimberly-Clark, Dude Wipes, InstaMed, Coffee+, Juice Plus+
Kimberly-Clark promotes Suzana Blades to general counsel; Dude Wipes brand expands executive suite for first time since its founding with a chief product officer; and CEO changes at Juice Plus+, InstaMed and Everyday Dose.
HBW Insight - August 21, 2026
Kimberly-Clark promotes Suzana Blades to general counsel; Dude Wipes brand expands executive suite for first time since its founding with a chief product officer; and CEO changes at Juice Plus+, InstaMed and Everyday Dose.
HBW Insight - August 21, 2026
After 10-Year Dispute, US FDA Grants Hearing On Lannett Generic Concerta Withdrawal
The central factual issue for the hearing, possibly one of the first of its kind, on CDER’s proposal to withdraw Lannett’s methylphenidate ANDA is whether the generic has been shown to be bioequivalent to Janssen Pharmaceuticals’ Concerta.
Generics Bulletin - August 20, 2026
The central factual issue for the hearing, possibly one of the first of its kind, on CDER’s proposal to withdraw Lannett’s methylphenidate ANDA is whether the generic has been shown to be bioequivalent to Janssen Pharmaceuticals’ Concerta.
Generics Bulletin - August 20, 2026
Biosimilars Are Powering Henlius’ Global Biopharma Push
Chinese biologics specialist Shanghai Henlius Biotech tells Generics Bulletin how its biosimilars business is funding innovation, supporting global expansion and providing the platform for increasingly complex development programs and partnerships.
Generics Bulletin - August 20, 2026
Chinese biologics specialist Shanghai Henlius Biotech tells Generics Bulletin how its biosimilars business is funding innovation, supporting global expansion and providing the platform for increasingly complex development programs and partnerships.
Generics Bulletin - August 20, 2026
Outlook Bids On Lytenava’s Differentiated Position As It Readies To Enter The US
Outlook Therapeutics is positioning Lytenava as the only FDA-approved ophthalmic bevacizumab, occupying a distinct space from biosimilars used off-label in the US retina market.
Generics Bulletin - August 20, 2026
Outlook Therapeutics is positioning Lytenava as the only FDA-approved ophthalmic bevacizumab, occupying a distinct space from biosimilars used off-label in the US retina market.
Generics Bulletin - August 20, 2026
Ustekinumab Setback Tests Richter’s Expanding Biosimilar Business
Richter’s Usymro (ustekinumab) biosimilar launch has been put on hold over manufacturing compliance issues, complicating an otherwise improving Biotechnology story as new launches drive growth and breakeven moves closer.
Generics Bulletin - August 20, 2026
Richter’s Usymro (ustekinumab) biosimilar launch has been put on hold over manufacturing compliance issues, complicating an otherwise improving Biotechnology story as new launches drive growth and breakeven moves closer.
Generics Bulletin - August 20, 2026
Regeneron’s Lowy Bets Combinations Will Carry Its Oncology Business Past PD-1
Regeneron built a PD-1 franchise approaching $2bn in annual sales, then bet on antibody combinations, bispecifics and radiopharma. The biology is sound but execution, toxicity and trial design remain challenges.
In Vivo - August 19, 2026
Regeneron built a PD-1 franchise approaching $2bn in annual sales, then bet on antibody combinations, bispecifics and radiopharma. The biology is sound but execution, toxicity and trial design remain challenges.
In Vivo - August 19, 2026
The $2.2tn Efficiency Gap: Who Got Their Money’s Worth?
The top 15 drugmakers spent $2.2tn over a decade. Only BMS and Takeda destroyed value; Lilly, Novo Nordisk and AstraZeneca converted spending into outsized value.
In Vivo - August 19, 2026
The top 15 drugmakers spent $2.2tn over a decade. Only BMS and Takeda destroyed value; Lilly, Novo Nordisk and AstraZeneca converted spending into outsized value.
In Vivo - August 19, 2026